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Introduction: A pancreaticoduodenectomy is the reference treatment for a resectable pancreatic head
ductal adenocarcinoma. The probability of 5-year survival in patients undergoing such treatment is
5–25% and is associated with relatively high peri-operative morbidity and mortality. The objective of the
present study was to evaluate risk factors predictive of outcome for patients undergoing a pancreati-
coduodenectomy for a pancreatic adenocarcinoma.
Methods: This retrospective analysis incorporated data from the Vancouver General Hospital and the
British Columbia Cancer Agency (BCCA) from 1999–2007.
Results: The 5-year survival of 100 patients was 12% with a median survival of 16.5 months. Ninety-day
mortality was 7%. Predictors of 90-day mortality included age  80 years (P < 0.001) and an American
Society of Anesthesiologists (ASA) score = 3 (P = 0.012) by univariate analysis and age 80 years
(P < 0.001) by multivariate analysis. The identifiable predictive factor for poor 5-year survival was an ASA
score = 3 (P = 0.043) whereas a Dindo–Clavien surgical complication grade  3 was associated with a
worse outcome (P = 0.013). Referral to the BCCA was associated with a favourable 5-year survival
(P = 0.001).
Conclusions: The present study identifies risk factors for patient selection to enhance survival benefit
in this patient population.
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Introduction
Adenocarcinoma of the pancreas is a formidable therapeutic chal-
lenge. The incidence of pancreatic cancer is essentially equivalent
to the death rate.1 The majority of the patients present with sys-
temic disease and have a survival rate of less than 4% at 5 years.1,2
Approximately 15% of patients presenting with a pancreatic
adenocarcinoma have apparently localized disease at the time of
diagnosis and are candidates for surgical resection such as a pan-
creaticoduodenectomy (Whipple resection).3 The 5-year survival
for patients undergoing surgery for apparently curable disease is
low, ranging from 5–25%.4,5 In spite of these results, in the absence
of effective stand-alone systemic therapy, surgical resection
remains the only option for long-term survival.6,7
In most high-volume institutions, a pancreaticoduodenectomy
is associated with mortality rates of less than 6%, but morbidity
can range from 30–60%.5,8 Further, the resource utilization for
pancreatic resections, especially a pancreaticoduodenectomy, is
demanding especially as it relates to pre-operative work-up, oper-
ating room requirements and length of hospital stay.9 Given the
suboptimal survival data in conjunction with peri-operative
mortality and morbidity, and resource requirements associated
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with a pancreaticoduodenectomy for a pancreatic adenocarci-
noma, it is essential to evaluate patient selection to optimize
overall outcomes.
The objective of the present study was to identify variables that
may help predict the outcome for patients undergoing a pancre-
aticoduodenectomy for a pancreatic ductal adenocarcinoma at the
Vancouver General Hospital (VGH), an academic teaching hospi-
tal of the University of British Columbia.
Methods
A retrospective chart review at VGH was undertaken to identify
patients who underwent a pancreaticoduodenectomy with cura-
tive intent for a ductal adenocarcinoma of the pancreas from 1
December 1999 to 31 December 2007. The date of final follow-up
was 25 April 2010. Data were extracted and cross-referenced from
the VGH Decision Support patient database, surgeon patient files
and the British Columbia Cancer Agency (BCCA) Information
Systems and Cancer Registry. Only patients with a pathologically
confirmed diagnosis of a pancreatic head ductal adenocarcinoma
undergoing a pancreaticoduodenectomy were included. Patients
were excluded if the pathological diagnosis could not be con-
firmed or if patients underwent a pancreaticoduodenectomy for
other disease processes including but not limited to an acinar cell
carcinoma, a cholangiocarcinoma, a duodenal carcinoma, carci-
noma of the Ampulla of Vater or neuroendocrine tumours.
Demographic, clinical, radiological and pathological data were
assessed. This included patient demographics: age, gender, surgi-
cal wait-times, co-morbidities; presenting symptoms: abdominal
pain, back pain, cholangitis, jaundice; radiological findings:
tumour size, a suspected lymphadenopathy, tumour relation to
vascular structures, metastases; surgical management: primary
surgeon, classic or pylorus-preserving resection; R status of resec-
tion (R0–R2 as documented by the pathology report indicating
status of tumour margins relative to resection margin), vascular
resection, peri-operative complications as defined by the Dindo–
Clavien classification,10 transfusion requirements; pathology:
intra-operative frozen sections, lymphovascular invasion,
perineural spread and TNM stage.11
Vital status for all patients was obtained from VGH Decision
Support Information Systems, BCCA Information Systems, sur-
geons’ files, referring physicians and/or family physicians. Some
data from patient charts older than 7 years were unavailable
because of their removal from the database. Cause and date of
death were verified from the BC Cancer Registry.
Ninety-day mortality was defined as death occurring less than
90 days from the date of surgery. Fisher’s exact test was used to test
for a relationship between each of the variables and 90-day mor-
tality. As a result of the small number of events, a logistic regres-
sion with Firth’s Penalized Likelihood was used for the 90-day
mortality multivariate analysis. Survival curves were calculated
using the Kaplan–Meier method and the log-rank test used as the
test of association for 5-year survival. Cox regression analysis was
used for the 5-year survival multivariate analysis. Variables were
considered for inclusion in the multivariate models if the P-value
in the univariate analysis was <0.1. A two-tailed 5% significance
level was used for the multivariate analysis. All analyses were
performed using SAS 9.2 (Vancouver, BC, Canada).
Results
One hundred and two patients from four surgical practices were
identified who met the inclusion criteria. Two patients were
excluded owing to a lack of sufficient follow-up data. One
hundred patients were available for analysis, with 16 (16%)
patients surviving beyond the last follow up date of 25 April 2010.
Of the 84 patients who died, 75 (89%) died as a consequence of
recurrent pancreatic cancer. The causes of death for the remaining
nine (11%) are unknown but were not cancer related. Overall, the
median survival was 16.5 months [95% confidence interval (CI):
13, 19]; 5-year survival was 12.1%, whereas the 90-day mortality
was 7%. Overall survival is shown in Fig. 1.
Patient characteristics evaluated for 90-day mortality are pre-
sented in Table 1. Factors predictive of 90-day mortality included
age  80 years (P < 0.001) or ASA score = 3 (P = 0.012). With
specific reference to age 80 years, three deaths occurring within
90 days were in this patient population (n = 7) compared with
four deaths in patients < 80 years (n = 93) (P < 0.001). From a
logistic regression, a patient who was <80 years was 34 times more
likely to survive 90 days past surgery compared with a patient who
was 80 years or over (95% CI: 4.4, 250.0). In the multivariate
analysis, age  80 years remained a statistically significant factor
(P < 0.001) whereas ASA score = 3 after adjusting for the effect of
age was no longer statistically significant (P = 0.068).
Patient characteristics evaluated for 5-year survival are pre-
sented in Table 2. Factors associated with poor survival at 5 years
included ASA score = 3 (P = 0.043) (Fig. 2), or development of
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Figure 1 Survival of all patients undergoing a Whipple resection for
pancreatic head ductal adenocarcinomas
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Table 1 Patient characteristics and 90-day mortality factors
Variable Level Survival <90 days Survival 90 days Fisher's P-value
Overall 7 93
Age Group <80 3 90 <0.001
80+ 4 3
Gender Female 2 41 0.696
Male 5 52
Wait time to surgery Missing 5 20 1.000
Less than 1 month 1 27
More than 1 month 1 46
Jaundice No 1 12 1.000
Yes 6 81
Surgeon 1 3 57 0.112
2 4 16
3 14
4 6
Weight loss No 7 67 0.185
Yes 26
Back pain No 6 80 1.000
Yes 1 13
Anorexia No 7 65 0.186
Yes 28
Symptom duration Missing 3 14 1.000
Less than 2 months 1 32
More than 2 months 3 47
Number of symptoms 0, 1 3 26 0.703
2 3 41
3, 4, 5 1 26
Tumour size Missing 1 6 0.677
2 4 43
>2 2 44
Positive nodal status Missing 1 6 0.194
No 2 56
Yes 4 31
ASA score Missing 4 0.012
1, 2 48
3 7 41
Complications Missing 13 0.131
0, 1 1 37
2, 3, 4 6 43
Arterial involvement Missing 1 9 1.000
No 6 76
Yes 8
Venous involvement Missing 1 11 1.000
No 6 73
Yes 9
Metastases Missing 2 13 1.000
No 5 78
Yes 2
Pre-operative biopsy Missing 1 0.674
No 4 64
Yes 3 28
All missing values are excluded from P-values.
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complication grade 3/4 (P = 0.013) (Fig. 3). Patients with an ASA
score of 1 or 2 had a median survival of 19.5 months (95% CI:
15.0, 24.0) compared with patients with an ASA score of III who
had a median survival of 12.0 months (95% CI: 7.0, 16.0).
This was the only identifiable pre-operative predictive factor
for a worse outcome. Post-operatively, patients with no or mini-
mal post-operative complications had a median survival of
19.5 months (95% CI: 15.0, 25.0) whereas patients with more
significant complications requiring invasive interventions has a
median survival of 12 months (95% CI: 9.0, 17.0). Referral to
BCCA was also associated with an improved 5-year survival rate
(P = 0.001) (Fig. 4) with a median survival of 18.5 months (95%
CI: 15.0, 24.0) compared with a median survival of 8.0 months
(95% CI: 2.0, 12.0) for non-referred patients. Neither chemo-
therapy nor radiation therapy had any significant impact on
5-year survival. Apart from the ASA score, there were no other
pre-operative predictive factors available for multivariate analysis
Table 2 Patient characteristics and 5-year mortality factors
Variable KM Log-rank
P-value 5 years
Age group (80+) 0.157
Anorexia 0.995
Arterial involvement 0.241
ASA 0.044a
Back pain 0.524
Biopsy 0.267
Referral to BCCA 0.002a
Gender 0.976
Hepatic resection 0.109
Jaundice 0.364
Metastases 0.268
Nodal Status 0.280
Number of symptoms 0.978
Positive node group 0.087
Complications 0.009a
Tumour size 0.347
Surgeon 0.531
Surgical wait time 0.441
Symptom duration 0.111
Venous involvement 0.773
Weight loss 0.330
aDenotes significance at 0.05.
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Figure 2 Effect of the American Society of Anesthesiologists (ASA)
score on overall survival
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Figure 3 Effect of post-operative complications on overall survival
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Figure 4 Effect of referral to the British Columbia Cancer Agency
(BCCA) on survival
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as surgical complications and BCCA referral and intervention
were considered post-operative events.
Biological factors (TNM stage, tumour differentiation, lym-
phovascular or perineural invasion) did not result in significant
differences in 5-year survival although the presence of metastatic
lymphadenopathy approached significance (P = 0.07) (Fig. 5)
with a median survival for node negative patients: 22.0 months
(95% CI: 12.0, 29.0); and node positive patients: 15.0 months
(95% CI: 9.0, 18.0).
Resection for curative intent (R0, R1) had a median survival of
17.0 months (95% CI: 14.0, 22.0). Median survival for patients
undergoing R2 resection was 13.5 months (95% CI: 1.0, 19.0) and
trended lower than those undergoing a resection with curative
intent, with two patients surviving to 1 year and no patients sur-
viving beyond 36 months. Resection of liver metastases had
a median survival of 9.0 months with one patient surviving
30 months (Fig. 6).
Discussion
Considering the mortality of an unresected pancreatic head ductal
adenocarcinoma and a lack of an effective alternative therapy as
stand-alone treatment, a pancreaticoduodenectomy remains the
gold standard baseline treatment for this disease. However, careful
patient selection that minimizes short- and intermediate-term
mortality and morbidity is required to ensure appropriate survival
benefit. The present study identified risk factors in 100 patients
undergoing a pancreaticoduodenectomy that are associated with
increased short-term (90 days) and long-term (5 years) mortality
rates. By identifying and modifying these risk factors, the utility of
a pancreaticoduodenectomy in this patient population may be
increased.
Patient physiology is an important factor to consider before
recommending surgery, even in the presence of technically resec-
table disease. In the present study, an ASA score of 3 is associated
with a higher 90-day and 5-year mortality rate. While age itself
should not be considered a contraindication for a pancreati-
coduodenectomy,12,13 octogenarians should be approached cau-
tiously, especially if they have any associated comorbidities
resulting in an ASA score of 3.
Careful patient selection and consideration of their ability to
sustain the physiological stress of a pancreaticoduodenectomy is
in part related to the likelihood of development of post-operative
complications. Intuitively, post-operative complications should
affect peri-operative mortality, but these complications also
impact 5-year survival rates.14,15 This may in part be secondary
to an associated immunologically compromised state associated
with development of more severe complications which increase
the risk of cancer recurrence.16 Minimization of post-operative
complications also emphasizes the necessity of meticulous and
precise intra-operative judgment and technical practices to reduce
the incidence and severity of complications. These operator-
dependent factors appear to influence both the peri-operative
outcomes as well as 5-year survival rates.17–19 While every effort
should be made to attempt resection of the tumour, these efforts
should be tempered by risk vs. benefit assessment. Individual
surgeons can only make an informed decision by knowing their
own data.
The concept of the borderline resectable pancreatic cancer
patient is an emerging state of disease primarily defined by CT
imaging criteria.20,21 In this series, the patients could not be spe-
cifically classified by these criteria. There was insufficient data
available to determine if involvement of major vascular structures
by imaging reports affected the 5-year survival rates. Similarly,
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Figure 5 Effect of lymph node metastases on survival
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resection of vascular structures or R resection status could not be
shown to influence intermediate- or long-term survival. However,
the numbers of R2 resections could suggest encroachment of the
tumour onto adjacent vascular structures and an inability to
resect all macroscopic disease. These are often patients that
require vascular resections and reconstruction leading to an
increased risk of post-operative complications. If pre-operative
imaging is suspicious for vascular involvement, then a pancreati-
coduodenectomy for high-risk patients (based upon age and ASA
score or significant co-morbidities) may not be advisable. Further,
patients who had a concomitant liver resection for metastatic
disease (n = 5) had a significantly worse outcome with only one
patient surviving to 1 year. Resection of a liver metastasis in this
setting is clearly beyond the borderline-resectable criteria and
should not be performed unless there are extenuating circum-
stances. What is not known is whether patients undergoing R2
resections or concomitant liver resections had an improved
quality of life.
A multidisciplinary and systematic approach to cancer therapy
has previously been shown to be beneficial in cancer care.22–24
The BCCA is a provincial agency providing a province-wide,
population-based cancer control programme for the residents of
British Columbia and the Yukon. The BCCA’s mandate covers the
spectrum of cancer care, from prevention and screening, to diag-
nosis, treatment and through to rehabilitation. The BCCA’s policy
in the management of pancreatic cancers has not, until recently,
included routine consideration of adjuvant chemotherapy. Radia-
tion therapy is administered only on a case-by-case basis. Referrals
to the BCCA had a positive effect on intermediate and long-term
survival in spite of the insignificant survival benefit of chemo-
therapy or radiation therapy. This may be secondary to the coor-
dinated, systematic medical and psychosocial therapy available
from BCCA that may be more efficient and more available to
referred patients than to those not referred for management.
As management of technically resectable pancreatic head adeno-
carcinomas continue to evolve, the criteria for selection
of patients for a pancreaticoduodenectomy requires continued
review. With an aging population and more sophisticated imaging
techniques available, the number of patients presenting for a
potential resection will increase. Careful evaluation of factors that
may result in a high likelihood of post-operative complications and
assessment, overall patient physiological must be undertaken to
ensure appropriate application of a physiologically stressful and
resource intensive procedure. Each institution should review its
own peri-operative morbidity and mortality data comparing the
risk of the procedure to its long-term results. Octogenarians with a
ASA score of 3 require a high degree of scrutiny to determine if the
risks of a pancreaticoduodenectomy justify the risks, especially if
there is any concern regarding the possibility of a borderline resec-
table cancer. Individual patient outcomes and institutional results
could be improved if the patients’ peri-operative risks justify the
long-term outcomes.As a corollary, the reduction of peri-operative
complications would significantly improve these outcomes.
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